Literature DB >> 11532385

Effects of the selective activation of 5-HT3 receptors on sleep: a polysomnographic study in healthy volunteers.

L Staner1, T Linker, M Toussaint, P Danjou, J C Roegel, R Luthringer, G Le Fur, J P Macher.   

Abstract

The respective role of various classes of central serotonin (5-HT) receptors in the regulation of sleep-wakefulness cycles has been the subject of many studies. Notably, it has been reported that 5-HT1A/B receptors are involved in the regulation of rapid eye movement sleep (REMS) and that 5-HT2A/C receptors participate in the control of slow wave sleep (SWS), but the role of 5-HT3 receptors is less well characterised. In this study we investigated the effects of SR 57227A, a potent and selective 5-HT3 agonist, on the sleep EEG of normal young male volunteers. SR 57227A (2.5, 5, 10, 20, 40 mg o.d. and 20 mg b.i.d.) or placebo were administered during 7 consecutive days in seven groups of ten subjects using a parallel group design. Sleep EEG recordings were performed on days 6 and 7 after an habituation session. SR 57227A produced a dose-dependent shift of REMS toward the end of the night without changing REMS and SWS duration nor altering sleep continuity. It suggests a role for the 5-HT3 receptor in the human sleep-wakefulness cycle and particularly in REMS regulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532385     DOI: 10.1016/s0924-977x(01)00099-2

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  2 in total

1.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.

Authors:  Steven C Leiser; Deborah Iglesias-Bregna; Ligia Westrich; Alan L Pehrson; Connie Sanchez
Journal:  J Psychopharmacol       Date:  2015-07-14       Impact factor: 4.153

2.  Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men.

Authors:  Sue Wilson; Astrid-Maria Højer; Jeppe Buchberg; Johan Areberg; David J Nutt
Journal:  J Psychopharmacol       Date:  2015-08-07       Impact factor: 4.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.